1. Germany Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA.DE
Heidelberg Pharma AGDE flagDeutsche Börse
2.71
EUR
+0.02
- -
126.79MMarket Cap
Heidelberg Pharma AG
HPHA.DE
(Deutsche Börse)

Recent

price

2.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
2.14
2.35
1.61
0.42
0.25
0.11
0.13
0.13
0.26
0.28
0.05
0.5
0.21
0.15
0.03
0.09
Revenue per Share
-5.13
-2.54
-1.37
-0.61
-0.66
-0.72
-0.51
-0.76
-0.41
-0.36
-0.61
-0.8
-0.53
-0.44
-0.42
-0.91
-0.51
Basic EPS, GAAP
-4.29
-1.7
-0.78
-1.77
-0.79
-0.55
-0.57
-0.58
-0.39
-0.34
-0.65
-0.86
-0.25
-0.74
-0.65
-0.68
-0.59
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-28.62
-25.48
-20.28
-17.43
-20.02
-19.52
-14.54
-12.72
-6.69
-7.05
-7.17
-7.31
-6.57
-5.69
-6.1
-7
-6.44
Book Value per Share
-0.55
-2.74
1.41
0.7
0.32
0.05
0.06
1.95
0.6
0.26
0.13
-0.07
1.55
0.87
0.47
-0.42
0.21
Tangible Book Value per Share
5
5
7
8
9
9
12
14
28
28
30
33
37
47
47
47
46
Basic Weighted Avg Shares
- -
12
16
13
4
2
1
2
4
7
8
2
19
10
7
1
4
Sales/Revenue/Turnover
- -
-114.26
-61.75
-75.18
-186.69
-303.81
-472.14
-570.77
-328.69
-141.79
-218.71
-1,473.87
-99.41
-284.99
-335.21
-3,227.99
-671.67
Operating Margin (%)
- -
1
1
2
- -
- -
- -
- -
- -
1
1
1
1
1
1
3
1
Depreciation Expense
-23
-14
-9
-5
-6
-7
-6
-11
-12
-10
-18
-26
-20
-20
-19
-42
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-118.89
-58.18
-37.85
-158.49
-286.85
-469.09
-577.38
-318.21
-138.84
-216.41
-1,493.64
-106.42
-206.38
-282.98
-2,901.15
-557.16
Profit Margin (%)
-3
-12
8
2
- -
-1
- -
27
15
5
1
-6
60
37
40
17
43
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-5
20
15
12
9
10
37
26
16
13
7
67
49
31
-11
19
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Aug'24
Nov'24
May'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
115
110
156

Working Capital

FRC

•

in mil. unless spec.
Aug'24
Nov'24
May'25
Total Current Assets
52
48
49
Cash, Cash Equivalents & STI
37
29
33
Accounts Receivable, Net
- -
- -
- -
Inventories
12
11
13
Total Current Liabilities
9
8
6
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
84.24%
129.62%
-135.37%
Free Cash Flow
41.71%
47.3%
5.55%
Net Income, GAAP
27.79%
26.87%
118.15%
Sales/Revenue/Turnover
93.01%
144.51%
-78.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
3
1
2
7
2025
1
- -
- -
- -
1
2026
3
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.09
- -
- -
-0.42
2025
-0.13
-0.14
- -
- -
-0.91
2026
-0.09
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Decoy Therapeutics Inc. (DCOY)
IMV Inc. (IMV)
Biora Therapeutics, Inc. (BIOR)
BioMarin Pharmaceutical Inc. (BM8.F)
Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
Sesen Bio, Inc. (SESN)
Business
Heidelberg Pharma AG, a clinical-stage biopharmaceutical company, develops innovative antibody-drug conjugates (ADCs) for targeted oncology therapies, focusing on its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform that utilizes Amanitin from the green death cap mushroom to overcome tumor resistance and eliminate dormant cancer cells in hematologic and solid tumors. The company advances a pipeline of ATAC candidates, including lead product HDP-101, a BCMA-targeted ATAC in Phase I/IIa clinical trials for relapsed or refractory multiple myeloma with dosing advanced to Cohort 9 at 175 µg/kg showing favorable safety, no dose-limiting toxicities, and early efficacy signals such as a very good partial response in one patient; HDP-102 for non-Hodgkin lymphoma; HDP-103 for metastatic castration-resistant prostate cancer; HDP-104 for gastrointestinal tumors; and HDP-201, an exatecan-based ADC for colorectal cancer; while also offering an ADC toolbox with diverse payloads and out-licensing legacy assets like girentuximab (Zircaix/TLX250-CDx) for renal cancer imaging and upamostat. Operations span Germany, the United States, and international markets through partnerships including Takeda and Telix Pharmaceuticals. Founded in 1997 as Wilex Biotechnology GmbH in Munich, the company restructured in 2011 with the acquisition of Heidelberg Pharma Research GmbH, relocated its headquarters to Ladenburg near Heidelberg, Germany, and changed its name to Heidelberg Pharma AG, listing on the Frankfurt Stock Exchange's Prime Standard (HPHA.DE). Recent developments include amending a royalty financing agreement with HealthCare Royalty in March 2025 for a USD 20 million upfront payment on TLX250-CDx royalties, extending cash runway into 2027 amid delayed FDA approval; reporting nine-month 2025 financials with reduced operating costs and focus on HDP-101; and advancing clinical progress in HDP-101 trials as of September 2025.